The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2023 | Real-world safety and efficacy of cilta-cel in R/R multiple myeloma
Surbhi Sidana, MD, Stanford University, Stanford, CA, discusses a study evaluating the real-world efficacy of ciltacabtagene autoleucel (cilta-cel) in patients with relapsed/refractory (R/R) multiple myeloma. Often, inclusion and exclusion criteria for clinical trials are very stringent, which prevents several patients from being eligible for these trials. Results from this study demonstrate that the safety and efficacy of cilta-cel in the real-world is comparable to that of clinical trials, with very high response rates observed in patients. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
